Fig. 2From: PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysisNetwork of all treatment comparisons for the OS and PFS. The lines connect the regimens that were directly compared in clinical trails. The thickness of the lines corresponds to the number of RCTs. PD-1: Programmed death receptor 1 inhibitors; TP: Paclitaxel plus cis-platinum; FP: fluorouracil plus cis-platinumBack to article page